P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

• Florian Simon,
• Rudy Ligtvoet,
• Thomas Noesslinger,
• Jan-Paul Bohn,
• Julia Von Tresckow,
• Rüdiger Liersch,
• Tobias Gaska,
• Kathleen Jentsch-Ullrich,
• Michael Koenigsmann,
• Thomas Wolff,
• Ingo Schwaner,
• Dominik Wolf,
• Christof Schneider,
• Eugen Tausch,
• Stephan Stilgenbauer,
• Karl-Anton Kreuzer,
• Sandra Robrecht,
• Anna-Maria Fink,
• Moritz Fürstenau,
• Kirsten Fischer,
• Valentin Goede,
• Michael Hallek,
• Barbara Eichhorst

Affiliations

Florian Simon

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Rudy Ligtvoet

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Thomas Noesslinger

2 Hanusch Krankenhaus Wien, 3rd Medical Department for Hematology and Oncology, Vienna, Austria

Jan-Paul Bohn

3 Medical University of Innsbruck, Internal Medicine V, Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Innsbruck, Austria

Julia Von Tresckow

4 University of Duisburg-Essen, Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany

Rüdiger Liersch

5 Gemeinschaftspraxis für Hämatologie und Onkologie, Clemenshospital, Münster, Germany

Tobias Gaska

6 Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie, Paderborn, Germany

Kathleen Jentsch-Ullrich

7 Gemeinschaftspraxis für Hämatologie und Onkologie, Magdeburg, Germany

Michael Koenigsmann

8 Onkologisches Ambulanzzentrum, Hannover, Germany

Thomas Wolff

9 OncoResearch Lerchenfeld, Hamburg, Germany

Ingo Schwaner

10 Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany

Dominik Wolf

3 Medical University of Innsbruck, Internal Medicine V, Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Innsbruck, Austria

Christof Schneider

11 University of Ulm, Department of Internal Medicine III, Ulm, Germany

Eugen Tausch

11 University of Ulm, Department of Internal Medicine III, Ulm, Germany

Stephan Stilgenbauer

11 University of Ulm, Department of Internal Medicine III, Ulm, Germany

Karl-Anton Kreuzer

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Sandra Robrecht

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Anna-Maria Fink

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Moritz Fürstenau

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Kirsten Fischer

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Valentin Goede

12 St. Marien-Hospital, Department of Oncogeriatrics, Cologne, Germany

Michael Hallek

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

Barbara Eichhorst

1 University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany